Abstract 752P
Background
Adding pembrolizumab (P) to standard first-line chemotherapy +/- bevacizumab in cervical cancer significantly improved survival. However, more than half of patients (pts) will present a relapse before 12 months. Virtually all cases of cervical cancer are attributable to HPV infection. Preclinical evidence suggests that histone deacetylase inhibitor vorinostat (V), might be active in both HPV 16 and HPV 18 related infections and might improve immunotherapy efficacy giving the rationale for combining P + V in cervical cancer.
Methods
PEVOsq is an open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of P+V in pts with recurrent and/or metastatic squamous carcinomas. Pts had to be PD1/PD-L1 antagonist-naïve with no restriction in terms of prior lines of treatments. P dose was 200 mg Q3W IV, and V 400 mg QD PO. Sample size was determined using an A’Hern design. Primary endpoint was objective response rate (ORR) according to RECIST 1.1. Secondary endpoints included safety, progression-free survival (PFS), overall survival (OS), and duration of response (DOR).
Results
Among 112 included pts, 25 were included in the cervix cohort. Median age was 52 years [range(r): 31-75]. The median number of prior lines of therapies was 1 [r: 0-3]. Among 23 pts evaluable for activity criteria, ORR was 39.1% [95%CI: 19.7-61.5]. Median PFS was 4.2 months [95%CI: 2.3-8.2] and OS was 10.3 months [95%CI: 5.7-NR]. DOR was 15.2 months [95%CI 1.4-NR]. Grade 3/4 Treatment related AE were frequent (44%). Seventeen pts (68%) had at least one treatment interruption and/or dose reduction due to toxicity for V including hematotoxicity, gastrointestinal disorders, asthenia, and creatinine increase. Six pts (24%) had at least one administration delayed due to toxicity for P. Median dose intensity for V was 271.4 mg/j [r: 108.7 – 400]. Dose intensity for V was 271.1mg/d [r: 108.7-400.0] and 260.5mg/d [r: 199.4-400.0] in pts with ORR and others (SD/PD), respectively. Results according to PDL1, MSI, TMB and HPV will be presented at the meeting.
Conclusions
Combining P and V in cervical cancer was effective even though dose adaptations for V were frequent.
Clinical trial identification
NCT04357873, EudraCT 2019-003839-33.
Editorial acknowledgement
Legal entity responsible for the study
Unicancer.
Funding
ERAPerMED ANR Fondation ARC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11